Products for Research Use Only

Eribulin

CAT: 0804-HY-13442-01Size: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13442-01Size:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
CAS Number
253128-41-5
Product Name Alternative
B1939; E7389; ER-086526
UNSPSC
12352203
Hazard Statement
H301+H311+H331, H341, H351, H361
Target
ADC Payload; Apoptosis; Microtubule/Tubulin
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/eribulin.html
Purity
99.92
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
C=C1C[C@@](CC[C@@]2(C[C@@]3([H])O4)O[C@]([C@](O[C@](C5)([H])CC6)([H])[C@@]6([H])O7)([H])[C@@]4([H])[C@]7([H])[C@@]3([H])O2)([H])O[C@@]1([H])CC[C@](C[C@@H](C)C8=C)([H])O[C@]8([H])C[C@@](O[C@H](C[C@H](O)CN)[C@@H]9OC)([H])[C@]9([H])CC5=O
Molecular Formula
C40H59NO11
Molecular Weight
729.90
Precautions
H301+H311+H331, H341, H351, H361
References & Citations
[1]Okouneva, T., et al., Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008. 7 (7) : p. 2003-11.|[2]Smith, J.A., et al., Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry, 2010. 49 (6) : p. 1331-7.|[3]Towle, M.J., et al., Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res, 2011. 71 (2) : p. 496-505.|[4]Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10 (2) : 161-174.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
ADC Related
Clinical Information
Launched
Citation 01
Dev Cell. 2025 Mar 25:S1534-5807 (25) 00151-0.|iScience. 2022 Sep 6;25 (10) :105081.|J Control Release. 2025 Oct 14;388 (Pt 1) :114325.|NPJ Breast Cancer. 2025 Feb 17;11 (1) :17.|Res Sq. 2024 Sep 17.|Cell Rep Med. 2025 Apr 2:102053.|mBio. 2025 Aug 15:e0048425.|Molecules. 2025 Feb 14;30 (4) :895.